Adalimumab injection, a subsidiary of Jianyou Co., Ltd. (603707.SH), was approved by the US FDA

Zhitong Financial App News, Jianyou Co., Ltd. (603707.SH) announced that EmergeBiosciencepte.Ltd. (hereinafter referred to as “Emerge”), a wholly-owned subsidiary of the company, recently received approval for adalimumab injection (40mg/0.4 mL, 80mg/0.8 mL) (BLA number: 761216) issued by the US Food and Drug Administration (“US FDA”).

As a biosimilar, adalimumab injection was approved for marketing by the US FDA on December 17, 2021. The trade name is YUSIMRY. This product was originally owned by Coherus BioSciences. Adalimumab injections approved this time are interchangeable with Humira (Humira, adalimumab antigen research drug) injections approved in the US. Up to now, the company has invested about RMB 138.6667 million in R&D expenses in the adalimumab injection project.